I believe that you couldn't be more wrong about the number of companies who failed because they simply couldn't afford to take their product through what was necessary for approval. I'm speaking of companies that tried their product on the fast killing cancers, like pancreatic in spite of preclinical and early clinical data that indicated it was far more effective against something like colon cancer. They gambled on pancreatic because the trial would be smaller and shorter and that was all they could afford, when it failed they were out of business.
Sure, sometimes BP will purchase these product for potential future development, but sometimes they're just abandoned as the company goes out of business, or somehow struggles to stay in business, but can't afford the needed trials.
NWBO took on one of the toughest cancers known to man, yes they had delays, but they have succeeded, whether you believe it or not.
Gary
Market Data 
Markets 
